OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases.
The Company’s immunology research and development platform is focused on three areas: T-cell-based vaccination,
Immuno-Oncology (focus on myeloid targets), Auto-immunity & Inflammation.
The company utilizes several scientific and technological approaches including neoepitopes and agonist/antagonist monoclonal antibodies, all ideally positioned to fight cancer and autoimmune diseases. Its first-in-class pipeline offers a diversified risk profile, ranging from registrational stage to R&D.
These new generation products are optimized to better target key receptors of the immune response’s activation or regulation, thus allowing for longer therapeutic effects.
Passionate
about making a difference in the fields of immuno-oncology and autoimmune diseases through acting on immunological pathways.
Dedicated
to leveraging our existing research platform and assets to deliver first-in-class candidates in clinical development.
Partnerships
focused to ensure, through premier international pharma, clinical and academic collaborations, the fastest possible delivery of our product candidates to patients in need.
The company relies upon its international and complementary team of experts involved in the research and optimisation of drug candidates, pharmaceutical development and drug registration to develop the next wave of novel immunotherapies. Based in Nantes (Head Office) and Paris, OSE Immunotherapeutics has 50 employees and is listed on Euronext Paris.


Governance
-
Dominique COSTANTINI, MD, Immunology
Chairman and Director of Development
+ -
Alexis PEYROLES
Director, Chief Executive Officer
+ -
Maryvonne HIANCE
Vice Chairman & Director of Public Affairs
+ -
Nicolas POIRIER, PhD
Director representing the employee shareholders and Chief Scientific Officer
+
-
Jean-Patrick DEMONSANG
Director
+ -
Sophie BROUARD
Director
+ -
Brigitte DRENO, MD
Director
+ -
Didier HOCH, MD
Director
+
-
Gérard TOBELEM, MD
Director
+
-
Alexis PEYROLES
Chief Executive Officer
+ -
Dominique COSTANTINI, MD
Chairman & Director of Development
+ -
Maryvonne HIANCE
Vice Chairman & Director of Public Affairs
+ -
Frédérique CORALLO, MD
Chief Medical Officer, Autoimmune Diseases
+
-
Nicolas POIRIER, PhD
Chief Scientific Officer
+ -
Bérangère VASSEUR, MD
Chief Medical Officer, Immuno-Oncology
+ -
Emilienne SOMA, PharmD, PhD
Director of Pharma Program Development
+ -
Jean-Pascal CONDUZORGUES, PharmD
Qualified Person (QP)
+
-
Anne-Laure AUTRET-CORNET
Chief Financial Officer
+
Careers
OSE Immunotherapeutics offers the opportunity to join a stimulating and collaborative environment which is part of an international network of academic and industrial partners. When recruiting, we are looking for highly creative people with expertise to join an entrepreneurial team committed to developing breakthrough treatments for patients who need innovative therapeutic options.
If you are interested to join the team, please send your resume to recrutement@ose-immuno.com